Not Yet Recruiting

NCT Number: NCT07312565

Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage

Rationale: Aneurysms of different types are known to be associated. In literature, concurrence of intracranial- and aortic aneurysms is described. Screening for aortic aneurysms (AA) in patients with intracranial aneurysms (IA) or aneurysmal subarachnoid haemorrhage (aSAH) could be cost-effective and of significant importance to decrease morbidity and mortality. The available literature on the association between the two types of aneurysms is sparse and in general of poor methodological quality. This protocol presents a study to more adequately evaluate the association between IA and AA.

Objective: To investigate the occurrence of abdominal aortic aneurysms (AAA) in patients who experienced aSAH.

Study design: This single cohort prospective study will include patients who experienced aSAH. The study participants will receive an abdominal ultrasound of the aorta to detect an AAA.

Study population: aSAH patients from a prospective cohort trial in the Netherlands.

Main study parameters/endpoints: The primary outcome, which will be investigated in the here above described study population, is the number of AAA detected on abdominal ultrasound.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will not receive an intervention, but only a diagnostic imaging without radiation. The burden associated with this study are considered minimal and the risks negligible. An abdominal ultrasound is a non-invasive diagnostic method with no risks for the participant. The only possible existing burden to the participant is travel and appointment time with a risk of detecting an abdominal aortic aneurysm or other (occult) intra-abdominal pathologies. When an aneurysm, sub-aneurysm or other intra-abdominal pathology is detected, surveillance or treatment according to standard of care and guidelines will follow.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Aneurysm Abdominal Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal Aortic Diseases Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebral Aneurysm Ruptured Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Subarachnoid Hemorrhage Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This study will be a prospective single cohort study.

During the period of the study, all aSAH patients (from another prospective cohort trial) will be screened for inclusion eligibility. Eligible patients will be included as subjects in this study. Study subjects will receive an abdominal ultrasound (US) focused on the aorta. Detecting an AAA on abdominal US will result in the daily standard of care for AAA, including surveillance and possible treatment by medication, intervention or surgery.

Study sites This study will be conducted by the Department of Surgery in the main study location University Medical Center Leiden (LUMC) in collaboration with University Neurosurgical Center Holland (UNCH). Eligibility screening and inclusion will be performed by the LUMC.

To answer the research questions of this study, the US laboratory of the LUMC will perform US on the included patients.

The clinical (neurovascular) centers who included patients in the SPARTA trial are:

Haaglanden Medical Centre (HMC)
Amsterdam Universitary Medical Centre (AUMC)
Erasmus Medical Centre (EMC)
Radboud University Medical Centre (Radboudumc)
University Medical Centre Utrecht (UMCU)
Maastricht University Medical Centre (MUMC).

The data from the aortic-scan centers will be obtained and centralized analysis will be performed by the main study location LUMC.

Number of study subjects The investigators will include 233 subjects as one single cohort. In this study, the collected data and analysis will be compared to the general- and at-risk population.

Study duration During an initial period of 2 months, patients will be included as study subjects. Inclusion stops when the targeted number of study subjects (N=233) is reached. The study duration is expected to be around 1.5 years and the study period will end when all 233 study subjects had an abdominal US, or were excluded from the study during the study period for particular reasons.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In order to be eligible to participate in this study, a participant must meet all of the following criteria:

Patient is a study subject of the trial: Study on Prognosis of Acutely RupTured Aneurysms (SPARTA)(12)
Inclusion at least one year after aSAH
Written informed consent

By being a study subject of the SPARTA trial, the following criteria are applicable:

Confirmed diagnosis of SAH on CT-scan or lumbar puncture (in the presence of a negative CT-scan)
IA related SAH as confirmed with radiological imaging
Age 18 years or older at presentation
Written informed consent for the SPARTA-trial

Exclusion criteria

A potential participant who meets any of the following criteria will be excluded from participation in this study:

Patient is not a study subject of the SPARTA trial
Patient has Loeys-Dietz-, Marfan- or Ehlers-Danlos syndrome

Treatment and study plan

Primary outcomes

Occurrence of AAA

Time frame: 1 year

Main study parameter/endpoint The primary endpoint of this study will be the occurrence rate of AAA in the study population. This occurrence rate will be calculated as the proportion of all performed ultrasounds in the study group (N; %).

Secondary outcomes

Risk factors for AAA in aSAH patients

Time frame: 1 year

Secondary study parameters/endpoint As a secondary endpoint, the investigators will evaluate risk factors of having an AAA as an aSAH patient. Presence of these factors (i.e. smoking, aneurysmal disease in medical history, age, gender) will be calculated as the proportion of the total study population (N; %).

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Hamming, MD

CONTACT

[email protected]

+31655322609

Sponsors and collaborators

Lead sponsor

Leiden University Medical Center

Other

Registry information

Official study title

The Occurrence of Abdominal Aortic Aneurysms in Patients With Ruptured Intracranial Aneurysms

Acronym: TRACE-aSAH

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Dec 31, 2025
Registry last updated: Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting